World Cervical Cancer Elimination Day: The importance of HPV genotyping in cancer prevention

17 Nov 2026
World Cervical Cancer Elimination Day: The importance of HPV genotyping in cancer prevention
This World Cervical Cancer Elimination Day, highlighting the importance of HPV screening, comprehensive genotyping and self-sampling in supporting the global effort to eliminate cervical cancer.

HPV: A common infection, with serious consequences

According to the World Health Organisation (WHO), cervical cancer is the fifth most commonly diagnosed cancer in women globally, with approximately 604,000 new cervical cancer cases and 280,000 deaths recorded worldwide in 2024. However, cervical cancer is largely preventable through effective HPV screening, early detection of high-risk investigations and timely management of pre-cancerous changes.

Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide and the causative agent of cervical cancer, with approximately 80% of sexually active individuals expected to acquire an HPV infection during their lifetime. In women with normal cytology, high-risk HPV genotypes are predicted to account for a staggering 70% of infections and persistent infection of high-risk HPV is directly responsible for 99.7% of all cervical cancer cases worldwide. Data shows persistent detection of HPV infection is a highly sensitive predictor of progression to cervical cancer.

This highlights the significant role molecular diagnostics plays in the identification and prevention of cervical cancer worldwide.

Beyond detection: Why HPV genotyping matters

Not all HPV infections carry the same clinical risk.

HPV16 and HPV18 account for approximately 70% of cervical cancers worldwide, while other genotypes contribute to the remaining disease burden. Although detecting high-risk HPV is essential, identification of individual genotypes provides additional information that can support clinical management.

Comprehensive HPV genotyping offers several important benefits:

✓ Risk identification - Differentiating HPV genotypes associated with higher risk of cervical cancer.

✓ Monitoring persistence - Distinguishing persistent infections with the same genotype from newly acquired infections.

✓ Informed clinical management - Supporting genotype-based follow up and risk assessments.

✓ Epidemiological surveillance - Monitoring HPV genotype prevalence and evaluating the long-term impact of vaccination programmes.

AllplexTM HPV HR & HPV28: Comprehensive HPV detection and genotyping

Seegene offers molecular solutions to support different HPV testing requirements through its AllplexTM HPV HR and HPV28 detection assays.

AllplexTM HPV28 is unique in its ability to provide individual genotyping across all 28 targets, delivering detailed molecular information that can support risk management, monitoring and HPV epidemiological surveillance. The assay also enables the identification of multiple HPV genotypes within a single sample, providing a more comprehensive understanding of HPV infection.

AllplexTM HPV HR provides a targeted approach to high-risk HPV screening, including individual detection of 14 clinically relevant, high-risk HPV genotypes to support risk-based screening pathways.

Beyond comprehensive genotyping Seegene’s testing workflow offers opportunities to support more accessible cervical screening through the use of self-collected vaginal samples. Self-sampling can help overcome barriers such as discomfort, embarrassment and difficulties in attending appointments, potentially increasing participation, particularly in under-screened populations.

Integration of validated self-sampling pathways can help alleviate pressure on healthcare services, reducing the need for routine clinician-led sample collection appointments, freeing up clinical capacity and supporting more efficient use of NHS resources.

By combining individual HPV genotyping with self-collected sampling, AllplexTM HPV HR and HPV28 offer laboratories a comprehensive molecular testing solution that supports both clinical insight and screening accessibility.

Interested in learning more about Seegene AllplexTM HPV28? Contact the Mast molecular team to discover how comprehensive HPV genotyping can support your laboratory’s testing requirements.

1. World Health Organization. Human papillomavirus and cancer. World Health Organization. March 5, 2024. https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer

2. Singular Tools. HPV World. HPV World. 2023. https://www.hpvworld.com/